Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, has made proposals for co-development of the Antigen Express novel H5N1 avian influenza vaccine in China following a trip to Beijing by Dr. Minzhen Xu, the Antigen Express Vice-President of Biology.
